Overexpression of 17β-Hydroxysteroid Dehydrogenase Type 1 Increases the Exposure of Endometrial Cancer to 17β-Estradiol
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
CONTEXT: The local interconversions between estrone (low activity) and 17β-estradiol (potent compound) by 17β-hydroxysteroid dehydrogenases (17β-HSDs) can lead to high 17β-estradiol generation in endometrial cancer (EC). OBJECTIVE: Examine the balance between the 17β-HSDs reducing estrone to 17β-estradiol (types 1, 5, 12, and 7) and those oxidizing 17β-estradiol to estrone (2, 4, and 8), in EC. PATIENTS AND METHODS: Reducing and oxidizing 17β-HSD activities (HPLC) and mRNA level (RT-PCR) were assessed in normal post-menopausal (n = 16), peritumoral endometrium (normal tissue beside cancer, n = 13), and 58 EC (29 grade 1, 18 grade 2, 11 grade 3). RESULTS: Grade 1 EC displayed a shifted estrone reduction/17β-estradiol oxidation balance in favor of 17β-estradiol compared with controls. This was more pronounced among estrogen receptor-α (ER-α)-positive biopsies. Type 1 17β-HSD mRNA (HSD17B1 gene expression, real time PCR) and protein levels (immunohistochemistry) were higher in ER-α-positive grade 1 EC than controls. The mRNA coding for types 4, 5, 7, 8, and 12 17β-HSD did not vary, whereas that coding for type 2 17β-HSD was increased in high-grade lesions compared with controls. Three-dimensional ex vivo EC explant cultures demonstrated that 17β-HSD type 1 generated 17β-estradiol from estrone and increased tumor cell proliferation. Additional in vitro studies using EC cells confirmed that in the presence of 17β-HSD type 1, estrone induced estrogen signaling activation similarly to 17β-estradiol. Therefore, estrone was reduced to 17β-estradiol. CONCLUSIONS: Type 1 17β-HSD increases 17β-estradiol exposure in grade 1 EC, thus supporting tumor growth. This enzyme represents a potential therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Labrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., & Pelletier, G. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0031 · Cited by 544 · cited 4×
“Equal amounts of proteins (concentration determined by BC Assay protein quantitation kit; Uptima-Interchim) were loaded, and efficiency of blotting on the membrane was confirmed with J Clin Endocrinol Metab, April 2012, 97(4):E591–E601 jcem.”
BackgroundMethodInfluentialSteroid sulfatase: molecular biology, regulation, and inhibition
Reed, M. J., Purohit, A., Woo, L. W. L., Newman, S. P., & Potter, B. V. L. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0003 · Cited by 524
Integrated view on 17beta-hydroxysteroid dehydrogenases
Moeller, G., & Adamski, J. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.10.040 · Cited by 214
AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer
Rižner, T. L., Šmuc, T., Rupreht, R., Šinkovec, J., & Penning, T. M. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.10.009 · Cited by 159
Byrns, M. C., Duan, L., Lee, S. H., Blair, I. A., & Penning, T. M. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2009.12.009 · Cited by 116
Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma
Utsunomiya, H., Ito, K., Suzuki, T., Kitamura, T., Kaneko, C., Nakata, T., Niikura, H., Okamura, K., Yaegashi, N., & Sasano, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0040 · Cited by 85 · cited 1×
“availability in EC (13, 28, 33), and its inhibition has”
Background
Cited by
Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism
Rižner, T. L., & Penning, T. M. (2014) · Steroids · doi:10.1016/j.steroids.2013.10.012 · Cited by 217
“There was, however, a trend for a higher expression of AKR1C3 in G2/G3 cancers [88].”
BackgroundDelvoux, B., D'Hooghe, T., Kyama, C., Koskimies, P., Hermans, R. J. J., Dunselman, G. A., & Romano, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2851 · Cited by 59
Self-citationThe Significance of the Sulfatase Pathway for Local Estrogen Formation in Endometrial Cancer
Sinreih, M., Knific, T., Anko, M., Hevir, N., Vouk, K., Jerin, A., Frković Grazio, S., & Rižner, T. L. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00368 · Cited by 33
“There were no significant differences in mRNA levels of AKR1C3 (Rizner et al., 2006; Smuc and Rizner, 2009; Cornel et al., 2012), the expression of HSD17B7 was reported as decreased (Smuc and Rizner, 2009) or unchanged (Lepine et al., 2010; Cornel et al., 2012) and expression of HSD17B12 was unchanged (Smuc and Abbrev…”
BackgroundResultInfluentialIto, K., Miki, Y., Suzuki, T., McNamara, K. M., & Sasano, H. (2016) · Endocrine-Related Cancer · doi:10.1530/erc-15-0470 · Cited by 29
Konings, G. F., Cornel, K. M., Xanthoulea, S., Delvoux, B., Skowron, M. A., Kooreman, L., Koskimies, P., Krakstad, C., Salvesen, H. B., van Kuijk, K., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5004 · Cited by 26
Self-citation
Metadata
- Authors
- Cornel, K. M. C., Kruitwagen, R. F. P. M., Delvoux, B., Visconti, L., Van de Vijver, K. K., Day, J. M., Van Gorp, T., Hermans, R. J. J., Dunselman, G. A., & Romano, A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-04
- Volume
- 97
- Issue
- 4
- Pages
- E591-E601
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1976691013
- Cited by
- 64
- References
- 6
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overexpression of 17β-Hydroxysteroid Dehydrogenase Type 1 Increases the Exposure of Endometrial Cancer to 17β-Estradiol. https://app.cochat.ai/papers/10.1210/jc.2011-2994
- The paper
- Cornel, K. M. C., Kruitwagen, R. F. P. M., Delvoux, B., Visconti, L., Van de Vijver, K. K., Day, J. M., Van Gorp, T., Hermans, R. J. J., Dunselman, G. A., & Romano, A. (2012). Overexpression of 17β-Hydroxysteroid Dehydrogenase Type 1 Increases the Exposure of Endometrial Cancer to 17β-Estradiol. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2011-2994
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.